Nature Communications (Jun 2020)
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody
- Martina Geiger,
- Kay-Gunnar Stubenrauch,
- Johannes Sam,
- Wolfgang F. Richter,
- Gregor Jordan,
- Jan Eckmann,
- Carina Hage,
- Valeria Nicolini,
- Anne Freimoser-Grundschober,
- Mirko Ritter,
- Matthias E. Lauer,
- Henning Stahlberg,
- Philippe Ringler,
- Jigar Patel,
- Eric Sullivan,
- Sandra Grau-Richards,
- Stefan Endres,
- Sebastian Kobold,
- Pablo Umaña,
- Peter Brünker,
- Christian Klein
Affiliations
- Martina Geiger
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich
- Kay-Gunnar Stubenrauch
- Roche Pharma Research & Early Development, Roche Innovation Center Munich
- Johannes Sam
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich
- Wolfgang F. Richter
- Roche Pharma Research & Early Development, Roche Innovation Center Basel
- Gregor Jordan
- Roche Pharma Research & Early Development, Roche Innovation Center Munich
- Jan Eckmann
- Roche Pharma Research & Early Development, Roche Innovation Center Munich
- Carina Hage
- Roche Pharma Research & Early Development, Roche Innovation Center Munich
- Valeria Nicolini
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich
- Anne Freimoser-Grundschober
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich
- Mirko Ritter
- Roche Diagnostics, CPS Research and Development
- Matthias E. Lauer
- Roche Pharma Research & Early Development, Roche Innovation Center Basel
- Henning Stahlberg
- Center for Cellular Imaging and Nano Analytics, Biozentrum, University of Basel
- Philippe Ringler
- Center for Cellular Imaging and Nano Analytics, Biozentrum, University of Basel
- Jigar Patel
- Roche Sequencing, NimbleGen
- Eric Sullivan
- Roche Sequencing, NimbleGen
- Sandra Grau-Richards
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich
- Stefan Endres
- Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München
- Sebastian Kobold
- Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München
- Pablo Umaña
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich
- Peter Brünker
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich
- Christian Klein
- Roche Pharma Research & Early Development, Roche Innovation Center Zurich
- DOI
- https://doi.org/10.1038/s41467-020-16838-w
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
The clinical application of T cell bispecific antibodies (TCBs) is often limited by the lack of tumour-specific antigens. In this study, the authors present a strategy to increase TCB tumour-selectivity by adding an anti-CD3 moiety that can be specifically activated by tumor specific proteases in the tumor microenvironment.
